"Adding epcoritamab to R-CHOP chemotherapy demonstrated a 51% reduction in the risk of cancer progression or death in newly diagnosed DLBCL patients, a significant development for a disease where R-CHOP has been the standard for decades."
Genmab and AbbVie have reported compelling topline results from their Phase 3 EPCORE DLBCL-2 trial, indicating that the addition of epcoritamab to the standard R-CHOP chemotherapy regimen significantly improved outcomes for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL). This development holds substantial promise, as R-CHOP has been the established first-line treatment for DLBCL for nearly 25 years, despite its limitations in achieving complete cure for a notable proportion of patients. While these results are preliminary and await peer review and full data release, they represent a potential paradigm shift in the treatment landscape for this aggressive blood cancer.
The EPCORE DLBCL-2 trial, a global undertaking, focused on patients newly diagnosed with DLBCL who presented with an International Prognostic Index (IPI) score of 2 to 5, signifying a higher-risk disease. Participants were randomly assigned to one of two treatment arms. The experimental arm comprised six cycles of epcoritamab in combination with R-CHOP, followed by two additional cycles of epcoritamab. The control arm received six cycles of R-CHOP, followed by two cycles of rituximab.
The primary endpoint of the trial, progression-free survival (PFS), which measures the duration for which cancer remains in check, was assessed by an independent review committee. In the main cohort of patients with the highest-risk scores (IPI 3-5), the hazard ratio for progression or death was reported as 0.49, translating to the observed 51% reduction in risk. This same significant benefit was observed in the broader patient group with IPI scores ranging from 2 to 5, which was evaluated as a key secondary measure. The trial enrolled adult patients between the ages of 18 and 79.
The companies stated that the epcoritamab and R-CHOP combination was "generally well tolerated and consistent with the previously reported safety profiles of the individual agents." However, specific rates of side effects were not disclosed in the initial announcement. Epcoritamab, marketed as Epkinly, is a bispecific antibody administered via subcutaneous injection. It is currently approved in the United States for specific patient populations with relapsed or refractory DLBCL or follicular lymphoma, including in combination with other agents for follicular lymphoma. It is important to note that Epkinly carries a boxed warning for potential serious immune reactions, including cytokine release syndrome (CRS), which can manifest with fever and low blood pressure, and for potential neurologic toxicity.
The robust trial design, featuring randomization and independent assessment of the primary endpoint, lends significant credibility to the reported findings. However, several critical details remain undisclosed, necessitating a cautious interpretation of the results at this preliminary stage. The trial was open-label, meaning both patients and their physicians were aware of the treatment received, a factor that can sometimes introduce bias. Crucially, overall survival data, which measures the impact of treatment on patient longevity, has not yet been released. The total number of patients enrolled in the trial also remains unknown.
Further adding to the need for caution, one of the most prominent external voices commenting on the findings, Dr. Gilles Salles, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, was an investigator in the trial and has disclosed financial interests related to AbbVie and Genmab. While Dr. Salles described the results as having "the potential to be practice-changing," the absence of commentary from lymphoma specialists unaffiliated with the trial underscores the preliminary nature of these findings.
The history of attempting to improve upon the R-CHOP regimen for DLBCL has been marked by numerous Phase 3 failures. While the FDA did approve polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL in 2023, the overall landscape has seen limited breakthroughs in first-line therapy. Consequently, oncologists are likely to await the full dataset, including detailed survival statistics, comprehensive side effect profiles, and data on patient subgroups, before considering a change in clinical practice. Key missing pieces of information include the exact number of participants, the duration of follow-up, the incidence of serious adverse events, and whether the benefits observed were consistent across different age groups.
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma, with approximately 25,000 new cases diagnosed annually in the United States, according to figures cited by Genmab. The disease typically affects older adults. Common symptoms prompting diagnosis often include painless swelling of lymph nodes, particularly in the neck, armpit, or groin, accompanied by unexplained fever, drenching night sweats, unintended weight loss, and persistent fatigue. Individuals experiencing these symptoms for more than a couple of weeks are strongly advised to seek medical attention.
For patients currently diagnosed with DLBCL, established first-line treatment regimens remain the standard of care and frequently lead to a cure. It is imperative that patients do not delay commencing their recommended treatment while awaiting potential new therapies. Individuals may inquire with their oncologist about eligibility for clinical trials, and the federal ClinicalTrials.gov registry provides detailed information on ongoing studies, including this specific trial (NCT05578976).
The potential cost and accessibility of epcoritamab, should it receive approval for newly diagnosed patients, are important considerations. Bispecific antibodies are generally expensive, and their administration often necessitates close monitoring for immune-related adverse events, especially in the initial phases of treatment. This monitoring may pose challenges for patients residing far from major cancer treatment centers. For those facing significant financial burdens, manufacturer assistance programs and nonprofit organizations, such as Blood Cancer United (formerly the Leukemia & Lymphoma Society), may offer valuable support.
Genmab and AbbVie have indicated their intention to submit the trial data for presentation at an upcoming medical conference and to engage with regulatory authorities globally to determine the subsequent steps for potential approval.
Key Questions Answered:
What did the trial find? The addition of epcoritamab to R-CHOP chemotherapy resulted in a 51% reduction in the risk of cancer progression or death compared to R-CHOP followed by rituximab in patients newly diagnosed with DLBCL.
Are these results final? No, these are topline results announced by the companies. Full data have not yet been published or undergone peer review.
Is the combination available now? The combination of epcoritamab and R-CHOP is not currently approved for newly diagnosed DLBCL patients. Epcoritamab is approved only for certain patients with relapsed or treatment-resistant lymphomas.
Did the treatment help people live longer? Overall survival data has not been released, so the impact on patient longevity remains unknown at this time.
What are the main side effects? Specific rates of side effects were not disclosed. However, epcoritamab carries a boxed warning for cytokine release syndrome and neurologic toxicity.
What should newly diagnosed patients do? Patients diagnosed with DLBCL should commence their recommended treatment without delay. They should also discuss with their oncologist whether participation in a clinical trial might be a suitable option for them.
